Shawn Kumar of RhythmScience

Heart failure is one of the most complex and costly conditions in American healthcare. More than 6 million people are living with it right now. That number is heading toward 8 million by 2030, and we are spending over $18 billion a year on hospitalizations alone. The drugs are better. The devices are better. And yet the problem keeps growing.In this episode, C.W. Hall sits down with Shawn Kumar, founder and CEO of Rhythm Science, to talk about what it actually takes to deploy AI in a clinical setting to help care teams manage heart failure patients more effectively and more safely.Shawn brings serious credentials to this conversation. He spent years at Abbott launching the CardioMEMS insertable pulmonary arterial pressure device and has been working in the heart failure space for over a decade. That experience gave him a clear view of what technology can do and where the gaps remain.Together they dig into the Rhythm Science platform, its collaboration with Cedars-Sinai, and what clinical decision support AI looks like when it is built the right way versus when it is just adding noise to an already overwhelmed care team. They also cover GDMT titration complexity, the role of agentic care in data gathering, the reimbursement landscape for digital health, and why six years of focused development in this domain matters when hospitals and health systems are evaluating who to trust.This is a grounded, honest conversation about chronic disease management at scale. No hype. Just the real work.Find Rhythm Science at rhythm.io.Subscribe to Kinetic Innovators for more conversations with the people changing how healthcare is built and delivered.